--- title: "Agenus extends maturity of $5.09 million in notes" url: "https://aibio.space/news/agenus-extends-maturity-5-09-million-notes/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-29" section: "Debt Financing" tickers: "NASDAQ:AGEN" source: "https://www.sec.gov/Archives/edgar/data/1098972/000119312526296186/agen-20260629.htm" summary: "Agenus pushed back the maturity of $5.09 million of 2015 notes by eight months, to February 18, 2027, and extended the expiration of earlier warrants to Ju" --- By the aibio.space news desk. Sources - [Agenus Inc. 8-K (2026-07-06)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526296186/agen-20260629.htm) - [Agenus Inc. 10-K (2026-03-16): business](https://www.sec.gov/Archives/edgar/data/1098972/000119312526108632/agen-20251231.htm) - [Agenus Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526108632/) [AGEN](https://aibio.space/companies/agenus/) 2026-06-29 # Agenus extends maturity of $5.09 million in notes Tickers [AGEN](https://aibio.space/companies/agenus/) Agenus pushed back the maturity of $5.09 million of 2015 notes by eight months, to February 18, 2027, and extended the expiration of earlier warrants to June 25, 2031. The filing does not describe new cash from the deal. ## Key facts - **Company**: Agenus Inc. (NASDAQ: AGEN) - **News type**: Debt Financing - **Primary source**: [Agenus Inc. 8-K (2026-07-06)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526296186/agen-20260629.htm) *Trading screens with price charts. CC0, via rawpixel. The picture shows the field, not the companies named.* Agenus Inc. entered into an Amendment to Notes, Extension of Warrants and Sale of New Warrants on June 29, 2026 with existing noteholders. The company's Form 8-K, dated June 29, 2026 and signed by Chairman and Chief Executive Officer Garo H. Armen, lists the changes. The company extended the maturity of $5.09 million of senior subordinated promissory notes it issued to those holders in 2015, from June 20, 2026 to February 18, 2027. All other terms of the notes, including the interest rate, are unchanged. The filing names no placement agent, underwriter or financial advisor for the amendment. ## The warrants The amendment extended the expiration of three existing warrant groups to June 25, 2031. The 2022 A Warrants cover 65,000 shares and the 2022 B Warrants cover 32,500 shares, both at an exercise price of $3.25 per share. The 2025 C Warrants cover 67,500 shares. The company also issued new 2026 D Warrants to certain noteholders for 56,525 shares at $3.25 per share, expiring June 25, 2031. The 8-K says the shares underlying the new D Warrants will be registered for resale with the Securities and Exchange Commission within 90 days after June 29, 2026. The company issued the new warrants in reliance on the exemption in Section 4(2) of the Securities Act, as a transaction not involving a public offering. It says no commission or other payment was made for soliciting the issuance. The 8-K files the form of 2026 D Warrant as Exhibit 4.1. ## Cash and what the deal does not do The amendment is titled in part "Sale of New Warrants," but the 8-K's summary does not state a price for them or any cash the company received. The company gave the notes a longer life and the holders longer-dated warrants. The notes now mature on February 18, 2027, and the filing does not describe how that maturity will be met. The filing also gives no reason for the eight-month extension. ## A note on the filing's own references The 8-K refers to the original 2015 notes and to the warrants' exhibits as filed with a "February 2025 Current Report." The same 8-K says that earlier report was filed on February 26, 2015. The filing gives no explanation for the mismatch, and the two dates cannot both be right for the same report. ## The company's spending The company's 10-K, filed March 16, 2026, reports research and development expense of $79.3 million for 2025, down from $155.5 million for 2024. Cash used in operations was $77.2 million in 2025, down from $158.3 million in 2024. Both figures fell from 2024, the company's annual report shows. The 8-K gives no cash balance and does not place the $5.09 million against cash on hand. ## Risks the company describes The 10-K's risk factors say the company's product candidates may not reach approval, and that competitors' products or physicians' reluctance to switch could limit demand. The company also says clinical trials may show an apparent benefit that is greater than the real one. Those are the company's own warnings, and the amendment does not address them. ## What comes next The next dated item in the filing is the February 18, 2027 maturity of the 2015 notes. The company is to register the shares underlying the new D Warrants within 90 days of June 29, 2026. The 8-K does not describe what happens to the notes if they are not repaid or extended again. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story AGEN Agenus Inc. NASDAQ ยท United States Open the starter desk ## More in Debt Financing Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 Debt Financing ### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/) Oct 29, 2026 --- Source page: https://aibio.space/news/agenus-extends-maturity-5-09-million-notes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Agenus extends maturity of $5.09 million in notes", 2026-06-29, https://aibio.space/news/agenus-extends-maturity-5-09-million-notes/